Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents

Boaz, M J and Hayes, P and Tarragona, T and Seamons, L and Cooper, A and Birungi, J and Kitandwe, P and Semaganda, A and Kaleebu, P and Stevens, G and Anzala, O and Farah, B and Ogola, S and Indangasi, J and Mhlanga, P and Eeden, M V and Thakar, M and Pujari, A and Mishra, S and Goontilleke, N and Moore, S and Mahmoud, A and Sathyamoorthy, P and Mahalingam, J and Narayanan, P R and Ramanathan, V D and Cox, J H and Dally, L and Gill, D K and Gilmour, J (2009) Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents. Clinical and Vaccine Immunology, 16 (2). pp. 147-155. ISSN : 1556-6811; eISSN: 1556-679X

Preview

Archive 200908.pdf - Published Version Download (975kB) | Preview

Abstract

The gamma interferon (IFN-�) enzyme-linked immunospot (ELISPOT) assay is used routinely to evaluate the potency of human immunodeficiency virus (HIV) vaccine candidates and other vaccine candidates. In order to compare candidates and pool data from multiple trial laboratories, validated standardized methods must be applied across laboratories. Proficiency panels are a key part of a comprehensive quality assurance program to monitor inter- and intralaboratory performance, as well as assay performance, over time. Seven International AIDS Vaccine Initiative-sponsored trial sites participated in the proficiency panels described in this study. At each laboratory, two operators independently processed identical sample sets consisting of frozen peripheral blood mononuclear cell (PBMC) samples from different donors by using four blind stimuli. PBMC recovery and viability after overnight resting and the IFN-� ELISPOT assay performance were assessed. All sites demonstrated good performance in PBMC thawing and resting, with a median recovery of 78% and median viability of 95%. The laboratories were able to detect similar antigen-specific T-cell responses, ranging from 50 to >3,000 spot-forming cells per million PBMC. An approximate range of a half log in results from operators within or across sites was seen in comparisons of antigen-specific responses. Consistently low background responses were seen in all laboratories. The results of these proficiency panels demonstrate the ability of seven laboratories, located across three continents, to process PBMC samples and to rank volunteers with differential magnitudes of IFN-� ELISPOT responses. These findings also illustrate the ability to standardize the IFN-� ELISPOT assay across multiple laboratories when common training methods, reagents such as fetal calf serum, and standard operating procedures are adopted. These results are encouraging for laboratories that are using cell-based immunology assays to test HIV vaccines and other vaccines.

Item Type:	Article
Uncontrolled Keywords:	T-Cell, Immunity, Human, Immunodeficiency Virus, Vaccine, Clinical Trials Peripheral, Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents
Subjects:	Tuberculosis > Laboratory Research > Pathological HIV
Divisions:	Basic Science Research > Clinical Pathology
Depositing User:	Dr. Rathinasabapati R
Date Deposited:	03 Aug 2017 10:27
Last Modified:	02 Mar 2021 05:32
URI:	http://eprints.nirt.res.in/id/eprint/931

Actions (login required)

View Item